7-hydroxy-N,N,2-triMethyl-3-tosyl-3H-benzo[d]iMidazole-5-carboxaMide

 4‑Hydroxy‑N,N,2‑trimethyl‑1‑tosyl‑1H‑benzo[d]imidazole‑6‑carboxamide is a pivotal intermediate in the industrial synthesis of tegoprazan, a novel P‑CAB indicated for GERD and erosive oesophagitis. The benzimidazole core of 4‑Hydroxy‑N,N,2‑trimethyl‑1‑tosyl‑1H‑benzo[d]imidazole‑6‑carboxamide provides the essential heterocyclic framework for tegoprazan‘s activity as a H⁺/K⁺ ATPase inhibitor. In quality control contexts, 4‑Hydroxy‑N,N,2‑trimethyl‑1‑tosyl‑1H‑benzo[d]imidazole‑6‑carboxamide is designated as Tegoprazan Impurity 17 (also referred to as Tegorazan Impurity 19), making it an important reference standard for analytical method development, impurity profiling, and QC testing in tegoprazan manufacturing. The compound‘s dense array of functional groups—including a phenolic hydroxyl, a tertiary amide, and a tosyl‑protected imidazole—provides synthetic chemists with multiple handles for further elaboration. Because of its dual role as intermediate and impurity standard, 4‑Hydroxy‑N,N,2‑trimethyl‑1‑tosyl‑1H‑benzo[d]imidazole‑6‑carboxamide is supplied at multiple quality grades to meet different application needs.
 
Product Parameters